An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

Patients may have trouble finding two different types of insulin products made by Eli Lilly. The company said it's experiencing a shortage of its 10 mL vials of Humalog and Insulin Lispro Injection ...

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

Drugmaker Eli Lilly warned this week that two of its formulations of insulin would be temporarily out of stock through the beginning of April, citing a “brief delay in manufacturing.” The ...

Drugmaker Eli Lilly on Thursday warned against using its diabetes and obesity drugs for “cosmetic” weight loss, as the medications have exploded in popularity, resulting in shortages. In an open ...

Fact checked by Jennifer Klump Key Takeaways Insulin costs have declined over the past two years, and additional price cuts ...

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation ...

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

The Food and Drug Administration (FDA) approved Eli Lilly's drug tirzepatide Wednesday for the treatment of obesity. The injection, which will be sold under the brand name Zepbound, was approved ...

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...

Eli Lilly (NYSE: LLY) shares rose 6% in the premarket on Thursday after the drugmaker beat Wall Street expectations with its ...